Instrument Inactif

Autres langues Cytori Therapeutics Inc Nasdaq

Actions

US23283K1051

Recherche biotechnologique et médicale

Autres langues

30/09	Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
25/09	Cerenome to Hold CNSide® Business Update Call on September 30, 2026
22/09	Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives
16/09	Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division
10/09	Cerenome, Inc. Enters Into Up To $20 Million Senior Secured Financing Facility With 3i, LP With Royalty-Based Repayment
10/09	Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment
04/09	Cerenome, Inc. announced that it expects to receive $20 million in funding from 3i Fund
20/08	Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines
14/08	Cerenome: Q2 Earnings Snapshot
14/08	Cerenome, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
14/08	Cerenome Reports Second Quarter 2026 Financial Results and Business Update
13/08	Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives
06/08	Cerenome Selects XiFin Empower RCM for Revenue Cycle Management and Clearinghouse Services for CNSide Platform
03/08	Plus Therapeutics, Inc. - Cerenome Launches as an Integrated CNS Oncology Company
03/08	Plus Therapeutics, Inc. will Change its Name to Cerenome
03/08	Plus Therapeutics, Inc. will Change its Ticker to CNSY from PSTV
31/07	Cerenome Launches as an Integrated CNS Oncology Company
28/07	Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference
21/07	Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
16/07	Plus Therapeutics, Inc. And Genomic Testing Cooperative, LCA Partner To Integrate Next-Generation Sequencing Into The CNSide CSF Assay Platform
16/07	Plus Therapeutics, Genomic Testing Cooperative to Integrate NGS Technology Into CNSide CSF Assay Platform
16/07	Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
14/07	Plus Therapeutics, Inc. Highlights Updated NCCN CNS Cancers Guidelines and Reinforces Clinical Role of CNSide in Leptomeningeal Metastases Monitoring
14/07	Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring
30/06	Plus Therapeutics Advances REYOBIQ Clinical Trials and Manufacturing Progress